Coexpression of MUC 1 Glycoprotein with Multiple Angiogenic Factors in Non-Small Cell Lung Cancer Suggests Coactivation of Angiogenic and Migration Pathways 1

We investigated the expression of MUC1 protein and its relationship to the microvessel density and the expression of thymidine phosphorylase, vascular endothelial growth factor (VEGF), VEGF-receptor KDR, basic fibroblast growth factor (bFGF), and bFGF-receptor (FGFR-2) in non-small cell lung cancer. Although MUC1 expression was found equally in poorly and highly vascularized tumors, a significant coexpression with multiple angiogenic factors and their receptors was noted (P5 0.0002, 0.03, 0.19, 0.10, and 0.01 for thymidine phosphorylase, VEGF, KDR, bFGF, and FGFR-2, respectively). In multiple regression analysis, both angiogenesis and MUC1 expression were independent prognostic variables. The present study suggests the existence of an early genetic event leading to the activation of both migration and angiogenesis pathways in non-small cell lung cancer.

[1]  A. Giatromanolaki,et al.  c-erbB-2 and episialin challenge host immune response by HLA class I expression in human non-small-cell lung cancer. , 2000, Journal of immunotherapy.

[2]  J. Voynow,et al.  Respiratory carcinoma cell lines. MUC genes and glycoconjugates. , 1999, American journal of respiratory cell and molecular biology.

[3]  T. Mitsudomi,et al.  MUC1 mucin mRNA expression in stage I lung adenocarcinoma and its association with early recurrence. , 1999, The Annals of thoracic surgery.

[4]  A. Giatromanolaki,et al.  Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  M. Reddish,et al.  The anti-MUC1 monoclonal antibody BCP8 can be used to isolate and identify putative major histocompatibility complex class I associated amino acid sequences. , 1998, Cancer research.

[6]  T. Irimura,et al.  Expression of MUC1 and MUC2 mucins in gastric carcinomas: its relationship with the prognosis of the patients. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  A. Harris,et al.  MUC1 (episialin) expression in non-small cell lung cancer is independent of EGFR and c-erbB-2 expression and correlates with poor survival in node positive patients. , 1998, Journal of clinical pathology.

[8]  R. Brekken,et al.  Vascular endothelial growth factor as a marker of tumor endothelium. , 1998, Cancer research.

[9]  G. Pruneri,et al.  Depolarized expression of episialin (EMA, MUC1) in lung adenocarcinoma is associated with tumor progression. , 1998, Anticancer research.

[10]  Athens Greece,et al.  Comparative evaluation of angiogenesis assessment with anti-factor-VIII and anti-CD31 immunostaining in non-small cell lung cancer. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  I. Fidler,et al.  Macrophage-Derived Metalloelastase Is Responsible for the Generation of Angiostatin in Lewis Lung Carcinoma , 1997, Cell.

[12]  S. Fox,et al.  Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenes , 1997, Cancer research.

[13]  L. Pilarski,et al.  The breast mucin MUCI as a novel adhesion ligand for endothelial intercellular adhesion molecule 1 in breast cancer. , 1996, Cancer research.

[14]  J. Jass,et al.  Significance of MUC1 and MUC2 mucin expression in colorectal cancer. , 1996, Journal of clinical pathology.

[15]  J. Wesseling,et al.  A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. , 1996, Molecular biology of the cell.

[16]  S. Ménard,et al.  Macrophage infiltrate and prognosis in c-erbB-2-overexpressing breast carcinomas. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  C. Uherek,et al.  CD31/PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium , 1995, The Journal of cell biology.

[18]  Walsh,et al.  Prognostic significance of MUC1 epithelial mucin expression in breast cancer. , 1995, Human pathology.

[19]  A. Sonnenberg,et al.  Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components , 1995, The Journal of cell biology.

[20]  R. Bast,et al.  Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. , 1991, Cancer research.

[21]  M. Lan,et al.  Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. , 1989, Proceedings of the National Academy of Sciences of the United States of America.